Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272925 | 0.82 | NQO1 (0.34) | ALOX5 | |
| SCHEMBL2279816 | 0.80 | SLC6A4 (0.35) | ALOX5 | |
| SCHEMBL13242141 | 0.78 | GABRB3 (0.31) | — | |
| SCHEMBL13220752 | 0.78 | — | — | |
| SCHEMBL12884424 | 0.77 | BCL2 (0.33) | — | |
| SCHEMBL16373610 | 0.77 | SLC6A4 (0.37) | — | |
| SCHEMBL12889274 | 0.73 | ACKR3 (0.36) | ALOX5 | |
| SCHEMBL420547 | 0.72 | HSP90AA1 (0.32) | — | |
| SCHEMBL765894 | 0.72 | NQO1 (0.35) | — | |
| SCHEMBL657541 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-114206870-B | Tricyclic AKR1C 3-dependent KARS inhibitors | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | NOVARTIS AG (CH) | 2024-04-30 | — | — | US | disclosed |
| EP-4013500-B1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS AG (CH) | 2023-10-25 | — | — | EP | disclosed |
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20140024583-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-8501746-B2 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2013-08-06 | — | — | US | disclosed |
| EP-2514751-A1 | Azaindazoles useful as inhibitor of kinases | Vertex Pharmaceuticals, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090156615-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-2029572-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007143597-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007079199-A2 | SUBSTITUTED BIS-AMIDE METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, HOLDING, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7183411-B2 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-27 | — | — | US | disclosed |
| US-20040157865-A1 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-08-12 | — | — | US | disclosed |
| WO-2004007459-A2 | NAPHTHOL, QUINOLINE AND ISOQUINOLINE-DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315582-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | ALOX5 3945/4885 |
| US-20090156615-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | ALOX5 98/4885 |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | ALOX5 4018/4885 |
| US-20250179072-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | ALOX5 3945/4885 |
| US-11970497-B2 | Tricyclic AKR1C3 dependent KARS inhibitors | AKR1C2, AKR1B1, AKR1C1 | ALOX5 3945/4885 |
| US-20040157865-A1 | Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor | OPRL1, VRK1, OPRK1 | ALOX5 3094/4885 |
| US-20240262827-A1 | TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS | AKR1C2, AKR1B1, AKR1C1 | ALOX5 3945/4885 |
| US-20140024583-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | ALOX5 98/4885 |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | ALOX5 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.